investigational
-
US FDA clears investigational new drug application, phase 2B trial for Immuron’s NASH/Fatty liver therapeutic
Immuron announced that the United States Food and Drug Administration (US FDA) had cleared an Investigational New Drug (IND) submission to commence a Phase 2b clinical trial of its bovine colostrum-derived therapeutic (IMM-124E) for the treatment of Non-Alcoholic Steatohepatitis (NASH) and Fatty Liver.
investigational | 06 March 2012
-
Vorapaxar’s data presented at AHA, published in NEJM
Researchers presented and published results from TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome), the first clinical outcomes trial of vorapaxar, the investigational Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonist from Merck (known as MSD outside the US and Canada).
investigational | 18 November 2011
-
Investigational oral MS therapy significantly reduced relapse rate
Findings from two-year phase 3 trial published in New England Journal of Medicine.
investigational | 06 October 2011
-
Forest Laboratories and Gedeon Richter announce positive results with investigational antipsychotic agent
Data showed that cariprazine-treated patients with acute manic episodes experienced significant symptom improvement compared to placebo-treated patients.
investigational | 05 October 2011
-
Roche’s investigational medicine T-DM1 shows improvement in progression-free survival compared to standard
First randomised trial of an antibody-drug conjugate (ADC) for metastatic breast cancer highlights importance of personalised approach to cancer care.
investigational | 26 September 2011
-
CEL-SCI receives key Chinese patent for its investigational cancer therapy Multikine
CEL-SCI Corporation announced that the Chinese patent office has issued a key patent covering CEL-SCI’s investigational cancer drug, Multikine (Leukocyte Interleukin, Injection). The patent, Chinese patent number ZL200480025403.6, is titled, “A M…
investigational | 18 August 2011
-
Roche’s investigational treatment for asthma meets primary endpoint in phase 2 study
Lebrikizumab has potential to be the first personalized treatment for asthma.
investigational | 04 August 2011
-
FDA makes recommendation on investigational compound dapagliflozin
Bristol-Myers Squibb company and AstraZeneca reported the outcome of the US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting on the New Drug Application for the investigational compound dapagliflozin.…
investigational | 20 July 2011
-
Merck’s investigational ophthalmic medication meets primary endpoint
Merck's investigational prostaglandin analogue ophthalmic medication tafluprost has met the primary endpoint in a phase 3 study. Data showed that patients with open-angle glaucoma or ocular hypertension, who were dosed once-daily with tafluprost, exp…
investigational | 02 May 2011
-
Phase 3 study of investigational compound Ipilimumab achieves primary endpoint
Bristol-Myers Squibb company announced that a clinical trial--known as study 024--of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma. Study 0…
investigational | 22 March 2011
